ASTH Stock Forecast & Price Target

Astrana Health is well-positioned in the healthcare industry with its strong partnerships and technology solutions, which have led to its success in multiple programs. However, the stock is currently undervalued and has potential for significant growth from transitioning members to global risk contracts and utilizing AI technology. The company's future success and financial growth will depend on its payer partnerships and changes in healthcare legislation. With potential for margin expansion and organic revenue growth, the company has a positive outlook for the first quarter and a price target of $47.

Astrana Health is a patient-centered, physician-centric integrated population health management company that is focused on providing coordinated, outcomes-based medical care cost-effectively. While the company's three reportable segments have shown strong performance and a track record of managing costs well, we believe organizations, such as Astrana, may face challenges in the value-based care basket as a whole as the market remains hesitant. Additionally, uncertainties remain around the recent acquisition of Prospect Medical, which adds a Knox Keene License and increases the company's full-risk arrangements, but also comes with a hospital stock with low or no top-line growth. While Astrana has a solid technology platform and a full-delegation model, with ~40% of members in full-risk arrangements expected to increase to ~60%-70% over time, there are potential risks and uncertainties related to the transition from fee-for-service to preventive healthcare.